Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY4 | P51582 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13893952 | 0.94 | P2RY4 (0.57) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL13893905 | 0.92 | MEN1 (0.74) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL11540883 | 0.92 | P2RY4 (0.61) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL13962358 | 0.88 | P2RY4 (0.48) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL13884828 | 0.88 | MEN1 (0.70) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL13135365 | 0.88 | NPC1 (0.65) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL375206 | 0.87 | TDP1 (0.52) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL10732288 | 0.85 | NPC1 (0.62) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL375375 | 0.84 | P2RY4 (0.50) | P2RY4NPC1RAB9ALMNAMAPK1 | |
| SCHEMBL14489853 | 0.83 | NPC1 (0.60) | P2RY4NPC1RAB9ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765508-B2 | Ocular mask having selective spectral transmission | AcFocus, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190314146-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | ACUFOCUS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10342656-B2 | Ocular mask having selective spectral transmission | ACUFOCUS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2785296-B1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | ACUFOCUS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180125639-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | ACUFOCUS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9848979-B2 | Ocular mask having selective spectral transmission | ACUFOCUS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170189167-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | ACUFOCUS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-9545303-B2 | Ocular mask having selective spectral transmission | ACUFOCUS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2785296-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | AcuFocus, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130268071-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | HEALTHCARE ROYALTY PARTNERS II, L.P. | 2013-10-10 | — | — | US | disclosed |
| WO-2013081094-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 (JP) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082545-A1 | OCULAR MASK HAVING SELECTIVE SPECTRAL TRANSMISSION | ACUFOCUS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| EP-1538154-B1 | Quencher composition comprising anthraquinone moieties | EXIQON AS (DK) | 2008-12-31 | — | — | EP | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-4702561-A | AMINOANTHRAQUINONE BISANIL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | P2RY4 358/4885NPC1 4101/4885RAB9A 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.